MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
MiNK Therapeutics (NASDAQ: INKT) announced an abstract acceptance for presentation at the American Thoracic Society (ATS) 2026 International Conference in Orlando, May 15-20, 2026. The abstract describes a combination of N-803 and investigational agenT-797 for unresolving Coccidioides immitis infection.
Presenter Terese Hammond, MD, will present Poster Board #103 in Session D107 on Wednesday, May 20, 2026, 11:00 AM–1:00 PM EDT. In line with ATS rules, no data or results are disclosed until the conference presentation.
MiNK Therapeutics (NASDAQ: INKT) reported Q4 and full‑year 2025 results and highlighted multiple 2026 clinical catalysts. Key facts: cash $13.4M at year‑end, an additional $3.0M raised post‑year, net loss $12.5M for FY2025, and advancing Phase 2 ARDS and GVHD programs with near‑term readouts.
Non‑dilutive funding includes a $1.1M C‑Further collaboration, an NIH NIAID STTR grant, and the Mary Gooze award, supporting clinical starts in 1H–2H 2026.
MiNK Therapeutics (NASDAQ: INKT) will report fourth quarter and full year 2025 financial results before market open on March 31, 2026 and host a conference call and webcast at 8:30 a.m. ET.
The company also highlighted platform expansion with a collaboration with C-Further and the University of Southampton to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers, citing non-dilutive funding and downstream commercial revenue potential.
MiNK Therapeutics (Nasdaq: INKT) announced a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.
The program receives up to ~$1.1 million in non-dilutive, aggregate funding for IND-enabling work and milestone-driven preclinical candidate nomination, plus a meaningful double-digit share of downstream commercial revenues; collaboration is non-exclusive.
C-Further unveiled its first two early-stage paediatric oncology programmes, CF-012 and CF-033, supported by an initial $40m (£30m) budget. CF-012 targets ETV6 for potential first-in-class inhibition in Ewing sarcoma. CF-033 is a PRAME-targeted allogeneic iNKT cell therapy developed with MiNK Therapeutics (NASDAQ: INKT) aimed at bone sarcoma, medulloblastoma and acute myeloid leukaemia. Projects will be advanced to preclinical candidate nomination subject to scientific milestones. Research partners include UVA Comprehensive Cancer Center, Dana-Farber, Mass General Brigham and University of Southampton. C-Further invites proposals with a submission deadline of 13 March 2026, and additional programmes are expected in 2026.
MiNK Therapeutics (Nasdaq: INKT) presented translational human lung data at Keystone Symposia (Feb 1–4, 2026) showing significant depletion of iNKT cells in lung-associated lymph nodes from end-stage idiopathic pulmonary fibrosis (IPF) patients.
Findings support a mechanistic role for iNKT insufficiency in advanced IPF and strengthen rationale for iNKT cell replenishment strategies to restore immune balance and support tissue repair in fibrotic lung disease.
MiNK Therapeutics (NASDAQ: INKT) and University of Wisconsin–Madison will initiate an investigator‑sponsored Phase 1 trial of allo‑iNKT cell therapy agenT‑797 to evaluate safety, tolerability, and preliminary efficacy for preventing graft‑versus‑host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation for high‑risk leukemias and other blood cancers.
The program is supported by two non‑dilutive awards: an NIAID STTR grant for preclinical development and a Mary Gooze Clinical Trial Award to fund enrollment, immune monitoring, and operations. AgenT‑797 is described as an off‑the‑shelf, HLA‑independent, lymphodepletion‑free donor‑derived iNKT therapy with prior favorable safety and immune‑modulating activity reported in solid tumors and ARDS.
MiNK Therapeutics (NASDAQ: INKT) on November 20, 2025 published preclinical data for MiNK-215, an allogeneic, IL-15–enhanced FAP-targeting CAR-iNKT designed to remove FAP+ cancer-associated fibroblasts and boost immune infiltration in solid tumors.
Key preclinical findings show MiNK-215: dismantles stromal barriers, selectively eliminates FAP+ fibroblasts, remodels the tumor microenvironment, activates dendritic cell and antigen-presentation pathways, repolarizes macrophages to a pro-inflammatory state, and enables deep tumor-specific T cell infiltration in refractory lung and MSS colorectal cancer models.
MiNK-215 is described as an off-the-shelf therapy manufacturable at scale to address solid tumors resistant to checkpoint inhibitors.
MiNK Therapeutics (NASDAQ: INKT) reported Q3 2025 results and clinical progress on its allogeneic iNKT platform. Key clinical highlights include durable responses with agenT-797 in checkpoint- and chemotherapy-refractory solid tumors, including complete remissions >2 years and multi-year survivors, with no ≥Grade 3 CRS or neurotoxicity reported.
The company launched an NIH- and philanthropically funded GvHD collaboration with UW–Madison and plans a Phase 2+ severe pulmonary disease trial using FDA-validated endpoints. Leadership additions target pulmonary, trauma, and biodefense expertise. Cash was $14.3M at 9/30/25 (plus $1.2M subsequent raise), providing runway through 2026.
MiNK Therapeutics (NASDAQ: INKT) reported updated SITC 2025 results for allo-iNKT therapy agenT-797 in PD-1–refractory solid tumors showing durable survival and immune reactivation.
Key findings include a reported median overall survival of ~23 months, multiple tumor-specific OS signals (e.g., germ cell >33+ months, thymoma >39+ months, gastric >27 months, cholangiocarcinoma >21 months), complete remission >2 years in one metastatic germ-cell patient, evidence of tumor-immune remodeling, and a favorable safety profile with no DLTs or Grade ≥3 CRS/neurotoxicity.